EMA accepts GSK’s bepirovirsen filing for chronic hepatitis B
GSK has moved bepirovirsen a step closer to market in Europe, announcing that the EMA has accepted the drug’s marketing authorisation application for review in adults with chronic hepatitis B. The candidate is an investigational antisense oligonucleotide, and the submission gives regulators their first formal look at a program GSK has positioned as a possible first-in-class, finite-duration treatment in a disease area where true functional cure remains uncommon. (stocktitan.net)
The filing builds on positive top-line phase 3 results GSK reported on January 7, 2026, from the pivotal B-Well 1 and B-Well 2 studies. Those trials evaluated bepirovirsen in more than 1,800 participants from 29 countries and met their primary endpoints, with GSK saying the program also achieved all ranked secondary endpoints. B-Well 2, listed on ClinicalTrials.gov, studied nucleos(t)ide analogue-treated adults with chronic hepatitis B and had actual enrollment of 857 participants; the paired B-Well program was designed to test whether a finite course of therapy could deliver sustained hepatitis B surface antigen loss and undetectable viral DNA after treatment ended. (gsk.com)
That treatment goal is what makes the program stand out. GSK defines functional cure in chronic hepatitis B as sustained loss of hepatitis B surface antigen, along with undetectable HBV DNA, for at least 24 weeks after a finite course of treatment. That’s a meaningful shift from the current reality, where many patients remain on chronic suppressive therapy and spontaneous or treatment-induced functional cure rates are typically low. The company has said bepirovirsen could become the first finite, six-month treatment option for chronic hepatitis B if approved. (gsk.com)
The broader disease burden helps explain why the application matters. Chronic hepatitis B affects more than 250 million people globally, and GSK has cited the disease as accounting for about 56% of liver cancer cases worldwide. A recent review also points to the scale of the unmet need, citing World Health Organization estimates of 254 million people living with chronic hepatitis B in 2022 and 1.1 million deaths annually. (gsk.com)
Direct outside expert reaction to the EMA acceptance itself appears limited so far, but industry commentary around the phase 3 readout has focused on the same theme: the possibility of moving chronic hepatitis B toward finite, functional-cure-oriented treatment. GSK’s own scientific leadership has described bepirovirsen as having the potential to transform treatment goals, while trade and investor coverage has emphasized the regulatory path now opening in Europe after the positive B-Well readout. That should be read cautiously until full phase 3 data are presented, but the direction of travel is clear. (gsk.com)
Why it matters: For veterinary professionals, this story sits outside companion-animal medicine, but it still has relevance as a signal of how nucleic acid-based therapeutics are maturing commercially and regulatorily. Antisense platforms have long been discussed as promising but operationally challenging; an EMA review in a large infectious-disease indication suggests regulators are increasingly comfortable evaluating these modalities on mainstream approval pathways. For clinicians and industry watchers alike, it’s also another example of drug development shifting from chronic disease control toward finite-course regimens with more ambitious endpoints. (stocktitan.net)
What to watch: The next catalysts are the full B-Well 1 and B-Well 2 data presentation and publication, both expected in 2026, plus any clarity on review timing from European regulators and on filings in the US and other markets. If the detailed dataset holds up, bepirovirsen could become an important test case for whether functional cure in chronic hepatitis B is ready to move from a research goal to a regulatory standard. (investing.com)